August 5, 2024 10:27 AM EDT
Financing

MBX Bio­sciences rakes in $63.5M for pep­tide ther­a­pies

Katherine Lewin

News Reporter

MBX Bio­sciences raised $63.5 mil­lion in a Se­ries C fund­ing round, two years af­ter clos­ing a $115 mil­lion Se­ries B. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Roche, Genen­tech end an­ti-tau Alzheimer’s drug col­lab­o­ra­tion with UCB

No­vo de­clares Phase 3 car­diac out­comes tri­al win for oral GLP-1

Aven­Cell gets $112M to build switch­able CAR-T ther­a­pies for ‘the last fron­tier’ of blood can­cers

Star­board takes ac­tivist stake in J&J con­sumer spin­out Ken­vue

Q3 biotech roundup: The 2024 turn­around sput­ters in­to a crit­i­cal Q4 fi­nale

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times